Shots:

• The P-III trial evaluates ANG-3777 (qd for 3days) vs PBO in a ratio (1:1) in 253 patients with kidney transplants who were at risk for developing DGF
• The trial failed to show a significant difference from PBO on the 1EPs of eGFR @12mos. The therapy demonstrated an inconsistent benefit on 2EPs. while overall safety profile was consistent with the overall experience in its clinical development program & consistent with the published literature in a patient population
• The results are not expected to support an indication in the studied DGF population. Additionally- the P-II exploratory trial of ANG-3777 for acute kidney injury associated with CSA-AKI is ongoing & results are expected in Q4’21

 ­ | Ref: Globe Newswire | Image: Businesswire